Analysts are raising their ratings and price targets on Verve Therapeutics stock today. Verve published very encouraging trial data for its VERVE-102 treatment yesterday. Investors think that the ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

Tvardi Therapeutics, Inc. (Nasdaq: TVRD), a clinical-stage biopharmaceutical company developing novel STAT3 inhibitors for fibrosis-driven diseases, visits the Nasdaq MarketSite in Times Square.

and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate ...

Verve Therapeutics is currently based in Cambridge ... In contrast, VERVE-102 uses a different LNP delivery system that incorporates GalNAc. This is a sugar molecule that can target specifically ...

(MENAFN- GlobeNewsWire - Nasdaq) Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACTTM platform to benefit from Dr. Langer's extensive scientific ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is preparing for the possible FDA approval of its weight loss drug candidate ...

Decoy's development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr. Langer's extensive scientific knowledge and experience CAMBRIDGE, Mass.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...